Clinical Trial Update: Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 2 evaluation of acalabrutinib in combination with R-CHOP as first-line treatment for mantle cell lymphoma (untreated).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituxan (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING